Literature DB >> 351804

Effects of naloxone on schizophrenia: reduction in hallucinations in a subpopulation of subjects.

S J Watson, P A Berger, H Akil, M J Mills, J D Barchas.   

Abstract

Endogenous opiate-like peptides (endorphins) are putative neuroregulators located throughout the mammalian brainstem. There is some evidence for their role in pain, stress, and affect. We report that the opiate antagonist, naloxone, alters some schizophrenic symptoms. In a double-blind, cross-over study, naloxone produced decreases in auditory hallucinations in some schizophrenic patients. This finding supports the hypothesis that the endorphins may play a roll in modulating hallucinations in a highly selected subgroup of chronically hallucinating schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 351804     DOI: 10.1126/science.351804

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  17 in total

1.  WIN 44,441: A Stereospecific and Long-Acting Narcotic Antagonist.

Authors:  P L Wood; C Pilapil; M Thakur; J W Richard
Journal:  Pharm Res       Date:  1984-01       Impact factor: 4.200

2.  Cortical opioid markers in schizophrenia and across postnatal development.

Authors:  David W Volk; Polina V Radchenkova; Erin M Walker; Elizabeth J Sengupta; David A Lewis
Journal:  Cereb Cortex       Date:  2011-08-01       Impact factor: 5.357

3.  Opioid peptides as neuroregulators: potential areas for the study of genetic-behavioral mechanisms.

Authors:  J D Barchas; S Sullivan
Journal:  Behav Genet       Date:  1982-02       Impact factor: 2.805

4.  The effects of naloxone on methylphenidate-induced mood and behavioral changes: a negative study.

Authors:  L Y Huey; D S Janowsky; L L Judd; N A Roitman; P L Clopton; D Segal; L Hall; D Parker
Journal:  Psychopharmacology (Berl)       Date:  1980-02       Impact factor: 4.530

Review 5.  Genetics and schizophrenic behavior.

Authors:  E Kahn
Journal:  Psychiatr Q       Date:  1980

6.  Clozapine inhibition of metenkephalin binding to synaptosome-enriched fractions of rat whole brain and hippocampus.

Authors:  E Somoza; C Franco; M Laviña; J A Fuentes
Journal:  Neurochem Res       Date:  1981-04       Impact factor: 3.996

7.  Brain opioids and autism: an updated analysis of possible linkages.

Authors:  T L Sahley; J Panksepp
Journal:  J Autism Dev Disord       Date:  1987-06

8.  Humoral-endorphin blood levels in autistic, schizophrenic and healthy subjects.

Authors:  R Weizman; A Weizman; S Tyano; G Szekely; B A Weissman; Y Sarne
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Immunoreactive beta-endorphin and adrenocorticotropin in human cerebrospinal fluid.

Authors:  K Nakao; S Oki; I Tanaka; K Horii; Y Nakai; T Furui; M Fukushima; A Kuwayama; N Kageyama; H Imura
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

10.  Assessment of naltrexone in the treatment of schizophrenia.

Authors:  M J Gitlin; R H Gerner; M Rosenblatt
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.